In breast cancer cell lines, decitabine increased expression of FUS1/TUSC2 despite lack of gene methylation[30], in keeping with the known ability of decitabine to increase gene expression through both methylation-dependent and methylation-independent mechanisms[1,2]. Here, TUSC2 is linked to breast cancer.